We should thank him. The WSJ article and resulting
Post# of 148281
(Total Views: 746)
Posted On: 08/26/2020 2:41:34 PM
Re: nicehedges #52358
We should thank him. The WSJ article and resulting inconsequential SP movement after 1.5 days of very tight consolidation could be a telling sign of the path of least resistance in the short term. So, again, thank you "at this time". I will keep holding my stock "at this time". Fwiw an 8% move in the stock is within 1 st. dev., yawn.
Aka, if it can't sink, then it floats.
Sidenote re: shorts: Uplisting does not lead to forced covering for some sort of technical reason as some here seem to have speculated (aka lender recall of shares ahead of div or proxy record dates for example). It could, however, scare shorts for a non-technical reason as uplisting would help legitimize the stock / expand investor base, allow for margin buying (can't margin OTC typically), and possibly lead to a quick price pop...
In the end, the fundamentals are what matters. Approval (in some form) is the true cure-all for this company. So far the science speaks for itself...the real risk in my mind is the politics involved.
As for the big pharma conspiracies, one thing to keep in mind is that Leronlimab can enable BP oncological drugs to work more effectively (from what I gathered from online video's, etc.)...so combo therapy wouldn't hurt BP revenue's but potentially help them...a friend to BP, not an enemy. Just a thought (happy to be corrected if I'm wrong by the pro's here).
Sincere thanks to the solid contributor's to this board.
Long & strong
Aka, if it can't sink, then it floats.
Sidenote re: shorts: Uplisting does not lead to forced covering for some sort of technical reason as some here seem to have speculated (aka lender recall of shares ahead of div or proxy record dates for example). It could, however, scare shorts for a non-technical reason as uplisting would help legitimize the stock / expand investor base, allow for margin buying (can't margin OTC typically), and possibly lead to a quick price pop...
In the end, the fundamentals are what matters. Approval (in some form) is the true cure-all for this company. So far the science speaks for itself...the real risk in my mind is the politics involved.
As for the big pharma conspiracies, one thing to keep in mind is that Leronlimab can enable BP oncological drugs to work more effectively (from what I gathered from online video's, etc.)...so combo therapy wouldn't hurt BP revenue's but potentially help them...a friend to BP, not an enemy. Just a thought (happy to be corrected if I'm wrong by the pro's here).
Sincere thanks to the solid contributor's to this board.
Long & strong
(3)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼